Coherus Oncology Inc expected to post a loss of 22 cents a share - Earnings Preview

What happened

Coherus Oncology is expected to report quarterly results on November 9 for the period ending September 30, 2026. Analysts expect revenue of $16.011 million, up 38.4% from $11.57 million a year ago, and a loss of 22 cents per share.

Confirmed

Global impact / market context

A wider customer base and higher revenue can help cover fixed costs, but a loss of 22 cents per share means expenses still exceed sales. Investors will compare actual results with estimates to judge whether the company is moving toward profitability.

Analyst inference

Analysts rate the shares a buy on average, and the median 12-month price target of $7.00 is far above the last close of $1.01. That gap suggests expectations for a recovery, making the upcoming results important for investor positioning.

Analyst inference

What to watch

1. Watch whether reported revenue reaches the $16.011 million estimate and whether the loss per share matches the expected 22 cents when results are released on November 9. Confirmed
2. Track whether the company explains how it plans to reduce its loss per share, since continued losses can require borrowed money or share sales that dilute existing owners. Proposed
3. Compare results with prior quarters, when Coherus beat estimates in some periods and missed in others, to judge whether analyst forecasts are reliable. Analyst inference

Evidence

• Original source link unavailable